ArticleClinical and experimental dental research2025
Assessing the Correlation Between Langerhans Cells Population and Prognosis of Tongue Squamous Cell Carcinoma.
Article in Clinical and experimental dental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectiveTongue squamous cell carcinoma (TSCC) is the most prevalent oral cancer. Despite considerable advancements in treatment, the 5-year survival rate remains relatively unchanged. Langerhans cells (LCs) play an important role in antitumor immunity. Therefore, we attempt to evaluate the correlation between the LC count and disease prognosis. MATERIALS AND
methodsHistopathologic slides from 24 cases, with at least 2 years of follow-up, were selected and categorized into early-stage (12 cases) and advanced-stage (12 cases) groups. An additional 12 slides of normal tissue comprised the control group. Immunohistochemical staining with the CD1a marker was performed to analyze the density of LCs. Statistical analysis assessed the impact of CD1a immune expression on patient survival and other variables such as age, gender, stage, and histopathological grade.
resultsComparison of CD1a+ cell counts across the three groups revealed a significant decrease in the advanced group. Furthermore, a lower count of CD1a+ cells correlated with poorer disease-free survival (DFS) (p < 0.001) and overall survival (OS) (p = 0.049). Although the CD1a+ cell count did not independently affect OS significantly (p = 0.210), it did show a significant impact on DFS as an independent variable (p = 0.002).
conclusionThe significant correlation between CD1a expression and patients' prognosis and survival rates suggests that CD1a+ cells could serve as a crucial prognostic factor in the management and treatment of TSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.